Literature DB >> 17270662

Unusual and underappreciated: small cell carcinoma of the prostate.

Jeffrey S Palmgren1, Saumil S Karavadia, Mark R Wakefield.   

Abstract

In recent years, attention has focused on the prognostic importance of neuroendocrine differentiation in prostate cancer. Focal neuroendocrine differentiation in prostatic adenocarcinoma is a frequent finding. Though controversial, the prevalence of neuroendocrine cells has been correlated with higher-grade malignancy and poor prognosis. As with other small cell tumors, production of ectopic neuropeptides has been reported. The rarity of the disease has precluded prospective randomized trials. Therapeutic regimens have mainly been modeled after those for small cell lung carcinoma. Here we review the literature to identify potential diagnostic, therapeutic, and prognostic factors. Evident from this review is the necessity for further research in the biology of small cell carcinoma progression, in order to improve therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270662     DOI: 10.1053/j.seminoncol.2006.10.026

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  65 in total

1.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

2.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Authors:  Charles C Guo; Jane Y Dancer; Yan Wang; Ana Aparicio; Nora M Navone; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2010-10-30       Impact factor: 3.466

Review 3.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

4.  Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Authors:  Wei Zhang; Bo Liu; Wenhui Wu; Likun Li; Bradley M Broom; Spyridon P Basourakos; Dimitrios Korentzelos; Yang Luan; Jianxiang Wang; Guang Yang; Sanghee Park; Abul Kalam Azad; Xuhong Cao; Jeri Kim; Paul G Corn; Christopher J Logothetis; Ana M Aparicio; Arul M Chinnaiyan; Nora Navone; Patricia Troncoso; Timothy C Thompson
Journal:  Clin Cancer Res       Date:  2017-11-14       Impact factor: 12.531

5.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Authors:  Himisha Beltran; David S Rickman; Kyung Park; Sung Suk Chae; Andrea Sboner; Theresa Y MacDonald; Yuwei Wang; Karen L Sheikh; Stéphane Terry; Scott T Tagawa; Rajiv Dhir; Joel B Nelson; Alexandre de la Taille; Yves Allory; Mark B Gerstein; Sven Perner; Kenneth J Pienta; Arul M Chinnaiyan; Yuzhuo Wang; Colin C Collins; Martin E Gleave; Francesca Demichelis; David M Nanus; Mark A Rubin
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

Review 6.  Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Authors:  Mary Nakazawa; Emmanuel S Antonarakis; Jun Luo
Journal:  Horm Cancer       Date:  2014-07-22       Impact factor: 3.869

7.  Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Ala Mustafa; Joseph W Fischer; Olya Witkowsky; Ajit K Verma
Journal:  Carcinogenesis       Date:  2012-09-13       Impact factor: 4.944

8.  Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

Authors:  Kenta Kawasaki; Yasuo Hamamoto; Takeshi Suzuki; Kenro Hirata; Yasutaka Sukawa; Akiyoshi Kasuga; Yuichiro Hayashi; Hiromasa Takaishi; Kaori Kameyama; Takanori Kanai
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

9.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

10.  Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report.

Authors:  Jingchao Wei; Xiaoping Zheng; Liuxun Li; Wensu Wei; Zhi Long; Leye He
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.